BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
See today's BioWorld Asia
Home
» CBMG takes Agreen's T cell immune therapy for $3.28M
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
CBMG takes Agreen's T cell immune therapy for $3.28M
Aug. 13, 2014
By
Shannon Ellis
No Comments
SHANGHAI – Cellular Biomedicine Group Inc., a stem cell and immunotherapy company headquartered in Shanghai, has acquired Beijing Agreen Biotech Co. Ltd. The deal will bring patents, people and the promise of revenue to its new owner.
BioWorld Asia